Arbutus Biopharma Receivables

Arbutus Biopharma's receivables stands at $180M as of June 2026. That compares with $1.1M in the prior-year period — up 15877.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Arbutus Biopharma reported $180M in receivables versus $1.1M a year earlier — a 15877.1% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.1M in the prior-year period — up 15877.1% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Arbutus Biopharma's receivables evolved across reporting periods, while the comparison chart places ABUS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Arbutus Biopharma's reading of $180M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.